Page 863 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 841

Tumor cell (Continued) Type II/β error (false negative), 343 Uterine tumors (Continued)
genetic instability and, 7 Tyrosinase, 362, 376 pathology and natural behavior of, 600
GLUT-1 and, 9
prognosis for, 600
Tyrosine kinase (TK), 257–258
VetBooks.ir heat shock protein 90 inhibitor and, 271 Tyrosine kinase inhibitor (TKI), 197–198 UTIs. see Urinary tract infections
therapy for, 600
microenvironment of, 49–50
molecular profiling and, 347
adaptive evolution and, 9–10 role of, 146
immunosuppressive barrier, 9 Tyrosine kinase receptor, types of, 146 V
secondary life, 54 cancer association and, 261t Vaccination
proteasome inhibition effect on, 270–271 Tyrosine protein kinase MET, canine for feline leukemia virus, 24–25
self-renewal of, 10–11 osteosarcoma and, 526 fibrosarcoma and, 93
spheres of, 11f TZL. see T-zone lymphoma for oral melanoma, 375–376
trapping of, 54 T-zone lymphoma (TZL), 700t Vaccine-associated fibrosarcoma, 138f
Tumor cell kill, 169 Vaccine injection site, observational studies for
Tumor cell line panel, 183–184 U cancer at, 87t–91t
Tumor cell lysate vaccines, 239 Ubiquitin-proteasome pathway (UPP), 270 Vaginal and vulvar tumors
Tumor cell resistance, 185–186 Ulnar transposition, for canine osteosarcoma, diagnostic techniques and workup for, 602
Tumor cell sensitivity, 183–185 538 extraluminal versus intraluminal, 601
Tumor endothelial cell, 264 Ultrasonography, 113–115 history and clinical signs of, 602
Tumor excision, levels of, 164, 165f–166f for adrenal gland neoplasia, 571–572 incidence of, 600–601
Tumor grading for adrenal medullary tumors, 573 pathology and natural behavior of,
differentiation and, 67 of carcinomatosis, 115f 601–602
importance of, 61 of interventional oncology, 174 prognosis for, 602
reflecting molecular mechanisms, for intestinal tumors, 463–464, 464f surgical excision of
67–69, 69t of multifocal nodule, 115f of intraluminal tumors, 602
for skin/subcutaneous tissue tumor, 355 radiography versus, 113–114 with ovariohysterectomy, 602
Tumor growth fraction, of soft tissue mass, 116f types of, 600–602
immunohistochemistry and, 71 Ultrasound-guided ethanol ablation, for Vaginal leiomyoma, 602
Tumor heterogeneity, 50 primary hyperparathyroidism, 582 Validation study, 92
Tumor hormone receptor, 606–607 Ultrasound-guided percutaneous ethanol Valproic acid (VPA)
Tumor immunosuppression, 233 injection, for feline hyperthyroidism, 580 efficacy of, 270
Tumor-induced mobilization, 54 Ultrasound-guided radiofrequency ablation role of, 270
Tumor-infiltrating lymphocyte (RFA), for primary hyperparathyroidism, Vascular collapse, 263–264
transfer, 242 582 Vascular endothelial cell tumor, as
“Tumor-initiating cell” hypothesis, 10–11 Ultraviolet irradiation, 16 conjunctival tumor, 675
Tumor margin, assessment of, 61, 69–70 skin cancer and, 352 Vascular endothelial growth factor (VEGF)
Tumor-node-metastasis, 354 Undifferentiated malignancy, 447 blood vessel creation and, 47–48
for oral melanoma, 368f UPP. see Ubiquitin-proteasome pathway in canine osteosarcoma, 533
Tumor-promoting inflammation, 7–8 Urban environment, 15–16 in canine sinonasal tumors, 495
neoplastic progression and, 49 Ureteral stenting, for malignant urethral dendritic cells and, 233–234
Tumor seeding, 159 obstruction, 175, 176f seminomas and, 628
Tumor sensitivity, 198 Urethral stent placement, for malignant Vascular endothelial growth factor receptor
Tumor stem cells, 211 urethral obstruction, 175 (VEGFR)
Tumor-stromal interaction, 54 Urethral tumor, 652 expression of, 54, 258
Tumor suppressor gene, 41t Urinary system tumors, 645–656 growth signaling pathways and, 264
apoptosis and, 6 canine urinary bladder tumors, 645–652 signaling, 258
cancer and, 43–44 feline urinary bladder tumors, 652 toceranib and, 263
canine osteosarcoma and, 525 renal tumor Vascular endothelial growth factor-A
disabling of, 1 canine, 652–653 (VEG-A), role of, 6
epigenetic methylation, 10 feline, 653 Vascular endothelium tumor, 138–139
retinoblastoma and, 43 urethral tumor, 652 Vascular ligation, 167
role of, 5–6 Urinary tract infections (UTIs), transitional Vascular normalization, 6–7
tumor formation and, 43 cell carcinoma and, 651–652 Vascularized ulnar transposition technique,
Tumor vaccine, 239–240 Urogenital system tumor, 134–135 538
approaches to, 239–240 Uroplakin III, 646 Vasculogenesis, 263
tumor antigens and, 239 Urticaria pigmentosa, 397 Vasculogenic mimicry, 53
using viral vector vaccines, 240 Uterine stump, 600 Vector targeting, 253f
Tumorigenic cell, as cancer stem cell, 50 mass at, 600f Vedaprofen, 293t–294t
Tunneling, needle core biopsy and, 159 Uterine tumors, 600 Vegetable, transitional cell carcinoma and,
TVT. see Transmissible venereal tumor diagnostic therapeutics and workup for, 600 645–646
Type I research, 344–345 history and clinical signs of, 600, 600f VEGF. see Vascular endothelial growth factor
Type I/α error (false positive), 343 incidence of, 600 VEGFR. see Vascular endothelial growth
Type II research, 344–345 ovariohysterectomy for, 600 factor receptor